Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
Oct 1 MYGN Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Oct 1 SNY Update: Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
Oct 1 SNY Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Oct 1 MYGN BMRN or MYGN: Which Is the Better Value Stock Right Now?
Oct 1 AMGN Fresenius Kabi wins FDA approval for Stelara biosimilar Otulfi
Oct 1 AMGN LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
Sep 30 AMGN Amgen must face lawsuit claiming it hid $10.7 billion tax bill
Sep 30 SNY Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 30 AMGN Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating
Sep 30 AMGN Prescription For Dividends: Why Amgen Is More Than Just A Safe Bet
Sep 29 AMGN Institutional investors may overlook Amgen Inc.'s (NASDAQ:AMGN) recent US$7.9b market cap drop as long-term gains remain positive
Sep 28 AMGN Amgen initiated with an Overweight at Cantor Fitzgerald
Sep 28 SNY Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Sep 27 SNY Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Sep 27 SNY Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Sep 27 SNY Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Sep 27 AMGN Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Sep 27 SNY Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Sep 27 SNY Sanofi, Regeneron get additional Chinese approval for Dupixent
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags